Reply #69: A little something more on Pasechnik and Regma Bio

[hang a left]

Regma Bio Technologies Limited is a new drug development company working to provide powerful alternatives to antibiotics. The company was founded by Caisey Harlingten and Dr Vladimir Pasechnik. Caisey Harlingten is an experienced and successful investor in intellectual property who has financed several science based start-ups that commercialise core technologies. Dr Vladimir Pasechnik is a research scientist with extensive experience in drug design and development. He spent over 10 years working at the Centre for Applied Microbiology and Research at the UK Department of Health in Salisbury. The company’s core technologies are focused on developing novel agents to combat microbial pathogens that can be delivered to the site of infection and treat diseased cells. With the growing decline in the efficiency of antibiotics new effective treatment are urgently needed. Regma considers that its technologies have the potential to provide powerful alternatives to antibiotics for the treatment of a variety of infections.


snip

21st August 2002 – Agreement with The Naval Medical Research Center (NMRC) of the US Navy

Regma Bio announces the signing of a Cooperative Research and Development Agreement with the Naval Medical Research Center (NMRC), a division of the U.S. Navy, in Silver Spring, Maryland. The intention of the agreement is to exploit the potential biological assets and capabilities of Regma Bio Technologies, Ltd. with respect to the diagnostic and therapeutic treatment of Anthrax and to jointly discover and develop capabilities that are either novel or build on existing capabilities of both parties.

The NMRC is a division of the Department of the Navy, United States of America, located in Silver Spring, MD. The mission of NMRC is to conduct research, development, tests and evaluations, and disease surveillance, in order to enhance the health, safety, performance and deployment medical readiness of Navy and Marine Corps.

snip

http://212.67.202.140/~biotech/News/London/PhageGen%20-%20regma_bio.htm